Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

CINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017. “Over the past year, Aerpio has made tremendous progress in the development of AKB-9778, our first-in-class Tie2-activator,” said Stephen Hoffman, MD, PhD, Chief Executive Officer of Aerpio. “In June 2017, we initiated our TIME-2b Phase

Full Story →